Cannabidiol for Schizophrenia
The Carlat Psychiatry Report, Volume 17, Number 1, January 2019
Michael Posternak, MD.
Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In this pilot study, investigators evaluated the benefits of cannabidiol (CBD), which is one of the two main active components of marijuana (the other being THC), for the treatment of schizophrenia.